Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 3, 1997, Pages 173-186

  Ballow, Charles H ^a   Jones, Ronald N ^b   Johnson, David M ^b   Deinhart, June A ^a   Schentag, Jerome J ^a  

^a MILLARD FILLMORE HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CEFALOTIN; CEFPODOXIME; CEFPROZIL; CEFRADINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINAFLOXACIN; ERYTHROMYCIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; METICILLIN; OFLOXACIN; OXACILLIN; PENICILLIN G; SPARFLOXACIN; STREPTOMYCIN; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; UNINDEXED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; CANADA; CONTROLLED STUDY; ENTEROBACTERIACEAE; HAEMOPHILUS; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0030668168     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)81807-X     Document Type: Article

References (39)

1. Alcaide F, Linares J, Pallares R (1995) In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 39:2243-2247.
2. Allegra L, Lonietzko N, Leophonte P, Hosie J, Pauwels R, Gungan JN, Petitpretz P (1996) Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomized, parallel, multicentre study. J Antimicrob Chemother 37(suppl A):93-104.
3. Aubier M, Lode H, Gialdroni-Grassi G (1996) Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies. J Antimicrob Chemother 37(suppl A):73-82.
4. Baquero F, Canton R (1996) In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 37(suppl A):1-18.
5. Barry AL, Fuchs PC, Brown SD (1997) Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. J Antimicrob Chemother 40:139-140.
6. Blondeau JM, Yaschuk Y, The Canadian Ciprofloxacin Study Group (1996) Canadian ciprofloxacin susceptibility study: Comparative study from 15 medical centers. Antimicrob Agents Chemother 40:1729-1732.
7. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wchsmuth IK (1991) Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 163:1279-1285.
8. Bochud PY, Eggiman P, Calandra T, van Melle G, Laghafi L, Francioli P (1994) Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31.
9. Bolmstrom A, Arvidson S, Ericson M, Karlsson A (1988) A novel technique for direct quantification of antimicrobial susceptibility of microorganisms. In: 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, Washington, DC: American Society for Microbiology (abstr 1209).
10. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR (1994) Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
11. Brown BA, Wallace RJ Jr, Flanagan CW, Wilson RW, Luman JI, Redditt SD (1989) Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother 33:1631-1633.
12. Brueggemann AB, Kugler KC, Doern GV (1997) In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 41:1594-1597.
13. Brumfitt W, Hamilton-Miller JMT (1993) Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin. J Antimicrob Chemother 31: 610-612.
14. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF, the Pneumococcal Sentinel Surveillance Working Group (1996) The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Preventions' Pneumococcal Sentinel Surveillance System. J Infect Dis 174:986-993.
15. Chaudry AZ, Knapp CC, Sierra-Madero J, Washington JA (1990) Antistaphylococcal activities of sparfloxacin (C1-978; AT-4140), ofloxacin, and ciprofloxacin. Antimicrob Agent Chemother 34:1843-1845.
16. Cohen MA, Yoder SL, Talbot GH (1996) Sparfloxacin world-wide in vitro literature. Diagn Microbiol Infect Dis 25:53-64.
17. Cormican MG, Jones RN (1996) Emerging resistance to antimicrobial agents in Gram-positive bacteria, enterococci, staphylococci, and non pneumococcal streptococci. Drugs 51(suppl 1):6-12.
18. Cunliffe NA, Emmanuel FXS, Thomson CJ (1995) Lower respiratory tract infection due to ciprofloxacin-resistant Moraxella catarrhalis. J Antimicrob Chemother 36:273-274.
19. Doern MA, Brueggeman A, Holley HP Jr, Rauch AM (1996a) Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208-1213.
20. Doern GV, Ferraro MJ, Brueggeman AB, Ruoff KL (1996b) Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891-894.
21. Fuchs PC, Barry AL, Pfaller MA (1993) Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin. J Clin Microbiol 31:2236-2237.
22. Gehanno P, Berche P, The Sinusitis Study Group (1996) Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J Antimicrob Chemother 37(suppl A):105-114.
23. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-146.
24. Jernigan DB, Cetron MS, Breiman RF (1996) Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): A strategy from the DRSP working group. JAMA 275:206-209.
25. Jones RN, Jacobs MR, Washington JA, Pfaller MA (1997) A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents: A 187 clinical laboratory center sample in the United States. Diagn Microbiol Infect Dis 27:75-83.
26. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluoroquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
27. Jorgensen JH, Howell AW, Maher LA (1992) Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the Etest. J Clin Microbiol 29:109-114.
28. Kayser FH, Wust J (1991) Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin. Eur J Clin Microbiol Infect Dis 10:163-166.
29. Klugman KP (1996) Epidemiology, control and treatment of multiresistant pneumococci. Drugs 52(suppl 2):42-46.
30. Klugman K, Goldstein F, Kohn S, Baquero F (1997) The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect 3(suppl 1):S45-S60.
31. Kojima T, Inoue M, Mitsuhashi S (1989) In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother 33:1980-1988.
32. Kojima T, Inoue M, Mitsuhashi S (1990) In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 34: 1123-1127.
33. National Committee for Clinical Laboratory Standards (1997a) Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A4. 4th edition. Villanova, PA: NCCLS.
34. National Committee for Clinical Standards (1997b) Performance standards for antimicrobial disk susceptibility tests: Approved standard M2-A6. 6th edition. Villanova, PA: NCCLS.
35. National Committee for Clinical Standards (1997c) Performance standards for antimicrobial susceptibility testing: Approved standard M100-S7. Villanova, PA: NCCLS.
36. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, the Scandinavian Sparfloxacin Study Group (1996) Oral empiric treatment of community-acquired pneumonia: A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 110:1499-1506.
37. Panililio A, Culver DH, Gaynes RP (1992) Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 13:582-586.
38. Pfaller MA, Jones RN (1997) Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagn Microbiol Infect Dis 29:199-201.
39. Washington JA, the Alexander Project Group (1996) A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994; The Alexander Project. Diagn Microbiol Infect Dis 25:183-190.